Effective prevention of cardiovascular events in high-risk patients - new indications for telmisartan

Joanna Dziwura; Krystyna Widecka

Vol 14, No 4 (2010)

Review paper

Published online: 2010-10-14

View PDF (Polish)

Download PDF file

Get Citation

Effective prevention of cardiovascular events in high-risk patients - new indications for telmisartan

Joanna Dziwura, Krystyna Widecka

Nadciśnienie tętnicze 2010;14(4):332-343.

Vol 14, No 4 (2010)

REVIEV

Published online: 2010-10-14

Abstract

Blockade of the renin–angiotensin–aldosterone system plays a pivotal role in the treatment of high blood pressure and prevention of target organ damage. Telmisartan is an angiotensin II receptor blocker displaying beneficial unique pharmacologic properties, metabolic effects, antihypertensive efficacy in monotherapy and combinations and good tolerance. Clinical studies confirm that telmisartan improves endothelial function, insulin sensitivity and lipid profiles, reduces arterial stiffness, left ventricular hypertrophy and the recurrence of atrial fibrillation. In addition, telmisartan improves renal function and has potential beneficial effects on prevention of cerebrovascular disease. The ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study has shown that telmisartan provides similar cardiovascular protection to ramipril in high-risk patients, while being better tolerated.
Arterial Hypertension 2010, vol. 14, no 4, pages 332-343.